Administering nasal insulin to children and infants who face strong risks of type 1 diabetes is not significant in preventing the disease from developing. The study will be published in the Lancet .
A research team at the University of Turku, Finland, analysed blood cord samples and entered some 264 high risk siblings into a trial of nasal insulin . The children were divided into insulin and placebo groups, and administering nasal insulin was found to not be effective in stopping the development of type 1 diabetes.
The authors reportedly commented: “Administration of nasal insulin did not delay or prevent type I diabetes in children with genetically conferred risk of disease, even when started soon after antibodies to the condition were detected.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.